Nexalin Technology (NASDAQ:NXL – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.28) EPS for the quarter, Zacks reports. Nexalin Technology had a negative return on equity of 187.59% and a negative net margin of 3,407.98%.
Nexalin Technology Trading Up 11.5 %
NXL traded up $0.23 on Friday, hitting $2.18. 107,176 shares of the company’s stock were exchanged, compared to its average volume of 1,354,446. The stock has a fifty day moving average of $2.87 and a two-hundred day moving average of $2.47. Nexalin Technology has a twelve month low of $0.35 and a twelve month high of $4.49. The firm has a market cap of $28.94 million, a PE ratio of -3.40 and a beta of 4.33.
Analysts Set New Price Targets
Separately, Maxim Group reaffirmed a “hold” rating on shares of Nexalin Technology in a report on Thursday, December 5th.
About Nexalin Technology
Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.
Read More
- Five stocks we like better than Nexalin Technology
- What Are Earnings Reports?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Russell 2000 Index, How Investors Use it For Profitable Trading
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What is the Shanghai Stock Exchange Composite Index?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
